RE: Warning letter received August 24th, 2017
Dear Mr. Randall Morris,
Please accept this letter as response to the warning letter received August 24th, 2017. In sum, as was previously demonstrated, the US Stem Cell Clinic (USCC) is not utilizing a biological drug product and therefore the regulations of part 210 and 211 (current good manufacturing practices) do not apply. The comments in the provided warning letter are specific to products that are produced in cGMP manufacturing facilities and classified as drugs according to the FDA. This is not something that a medical clinic would be required to follow. USCC is not manufacturing a drug. That being said, in an abundance of caution, US Stem Cell Clinic will immediately switch to 510(k) approved systems to process tissue in clinic such as bone marrow systems and/or fat systems.
Our facility has demonstrated sterile surgical techniques as required by the medical boards. It is inappropriate and harmful to state that our clinic is not sterile as we are completely compliant with the regulations for surgical procedures including using individually wrapped disposable sterile supplies, sterile field prep, and more. The strict regulations mentioned in the warning letter required to manufacture drugs are not applied to clinics or hospitals. As a clinic performing a medical procedure, we have strict and appropriate protocols in place to prevent contamination and breach of sterility. We are following the exact protocols that are utilized at surgical centers and hospitals. As you know, these protocols are very different than what is required for GMP manufacturing facilities. We have never had an incidence of contamination and the statements that were made in your warning letter and press release are misleading and causing irreparable harm.
We have previously described in detail why the FDA has wrongly defined these in clinic procedures as a drug and provided evidence. The evidence and summary is provided below. I would like to specifically call your attention to the fact that according to your current code of federal regulations, same surgical procedure is not subject to the rules for tissue banks which include minimal manipulation and homologous use. We strongly believe that it is a violation of the rights of American citizens to prevent them from seeking alternative care for their conditions as long as it does not violate regulations or the law. Our clinic is not violating the law as it is currently written. There is huge support from government officials and American citizens for stem cell treatmentsagain, while all laws are adhered to as we do. Please refer to just one petition out of many regarding stem cell treatments in clinic with almost 70,000 signatures: https://www.change.org/p/fda-don-t-shut-down-our-access-to-needed-stem-cell-therapy-treatment.
We would also like to address the comment in your warning letter regarding our firm impairing the ability to conduct the inspection. This statement is blatantly false and should be removed from the record. We provided access to every room in the facility and allowed pictures on multiple occasions. We also provided copies of all requested documents including confidential patient information. We are an extremely small firm with only a handful of employees most of which are part time or 1099 contract. As a small firm with limited resources, it is necessary to schedule the access that was required by the investigators in order to prevent permanent damage to our business. We provided abundant time and availability to the inspectors and on several occasions, the inspectors canceled last minute and did not come. At one point, the inspectors came to the office when the office was closed. During this last inspection, we worked with the inspectors for over a month providing hundreds of copies and burned CDs. On several occasions, I requested paper, printer ink and office supplies but did not receive what was requested. This inspection caused undue financial harm to our small firmyet we made our staff and resources available to the investigators at all times. Stating that we prevented or limited access to our company is an apparent attempt to disparage our company and we deem it both unprofessional and an unfair statement.
Given that we are a medical clinic that does not manufacture drugs, the guidance document that you referenced does not apply to our facility. Instead, USCC is performing a medical procedure wherein tissue is removed from a patient and re-implanted during the same surgical procedure. 21 C.F.R. 1271(b) titled Human Cells, Tissues and Cellular Tissue-Based Products, expressly states, you are not required to comply with the requirements of this part if you are an establishment that removes HCT/Ps from an individual and implants such HCT/Ps into the same individual during the same surgical procedure.
The procedure performed at USSC is simply the practice of medicine. Medical practitioners have been performing similar type procedures in clinic for decades including fat, skin, tendon/ligament, vascular, hair and bone grafts, bone marrow transplantation, and blood/plasma transplantation. Please keep in mind that many of these medical procedures may involve non-homologous use of tissue (CABG with vein graft or ileum to replace bladder) or more than minimal manipulation (skin grafts, hair transplants, or bone grafts). But because these are completed by medical practitioners during the same surgical procedure, the practitioners per the exception clause are not required to comply with the requirements of this part (1271) which includes details on products under section 351 vs. 361 PHS Act.
Therefore, the regulatory sections of Part 1271 regarding homologous use or more than minimal manipulation are not applicable to the procedures performed by USSC. To be clear, the purpose of stem cells inside our bodies is to maintain and repair damaged tissue, therefore any application of stem cells to patients would in fact be defined as homologous.
Even if USSC were somehow subject to the regulatory sections of Part 1271, the protocols utilized by USSC would be exempt from the regulations because the procedures practiced at USSC do not involve more than minimal manipulation. Part 1271 Regulations create a regulatory exemption from the manufacturing and labeling requirements that normally apply to drugs and biological products for any HCT/P that is no more than minimally manipulated. See 21C.F.R. 1271.10(a). Minimal manipulation of cells means processing that does not alter the-relevant biologicalcharacteristics. Id. 1271.3(f)(2).
In the procedures performed at USCC, the actual stem cells are not modified or changed in any way but instead separated via centrifugation. Even the collagenase digestion only changes the integrity of the extracellular matrix and does not change the characteristics of the cells themselves. These scientific facts were confirmed by several leading stem cell scientists at the September 2016 FDA hearing.
Medical procedures are already scrutinized and regulated by the state medical boards, legislatures, and agencies. In addition, the doctor patient relationship is protected and physicians take a vow to protect the safety, health and welfare of patients. They are dedicated to serving the interest of the patient and market forces, societal pressures, and administrative demands must not compromise this promise. The FDA is responsible for protecting the public health by assuring the safety, efficacy and security of drugs. The FDA does not regulate the practice of medicine or the bodies/tissues of individuals.
This same procedure is currently performed at thousands of clinics throughout the US. Notably, throughout the stem cell field, these clinics and practitioners also maintain that the procedures performed are medical procedures, and that the regulations of part 210 and 211 (current good manufacturing practices) do not apply.
We are aware that many clinics have been visited by the FDA without any actions or warnings letters. At USCC, we are following standard clinical procedures for medical facilities to ensure safety of the patients. This is considered a medical procedure because the tissue is removed from the patient and re-implanted during the same surgical procedure to the same patient (autologous use). The protocols used at our clinic have been well established in publications as both efficacious and safe. Over ten thousand patients have been treated using similar protocols with a strong safety record. Specifically, over 7000 patients have been treated using the exact same laboratory kit that we utilize at USCC.
Bone marrow and blood products are currently being utilized in the clinic in a similar fashion. The only reason bone marrow products are being regulated differently is because they predate the 1976 medical device amendments allowing for a 510k process instead of IND/IDE. There is no scientific or medical reason that fat tissue removed from a patient would be regulated differently than bone marrow or blood, when they are being used for the same purpose. According to recent publications, cells from fat tissue are demonstrating superior clinical results than bone marrow cells. This is most likely due to the fact that the bone marrow contains very high amounts of white blood cells (WBCs) which can cause unnecessary inflammation whereas fat has low amounts of WBCs. Fat tissue, however, may contain up to 500 times more stem cells. The rate of complications from taking a bone marrow aspirate is significantly higher than taking an adipose sample. The cells that are obtained from an adipose sample are separated from the adipocytes and have not been manipulated or changed in any way prior to reintroducing into a patient. According to reports, these therapies do not have the same negative side effects as many of the available drugs on the market.
We are aware that the FDA received comments on the published draft guidelines regarding adipose tissue procedures in clinic. We are also aware that the FDA held a public hearing regarding these topics in September 2016 in which many scientists, physicians and patients expressed support for these therapies. We are able to provide the FDA with any necessary information to demonstrate that this is a medical procedure that is safely done on an outpatient basis. Published results of outcomes to date have been overwhelmingly positive.
If the federal government were to interfere with a persons ability to obtain and utilize their own cells in their body to heal themselves, this could be a gross violation of the constitution. According to the constitution, Americans have a fundamental right to privacy as well as protection from undue government intrusion. Specifically, in the case of Griswold v. Connecticut 381 U.S. 479, 484-486 (1965), the Supreme Court recognized that specific guarantees in the Bill of Rights create zones of privacy to protect certain intimate activities from means which sweep unnecessarily broadly and thereby invade the area of protected freedoms. Regarding bodily integrity, the court ruled that no right is held more sacred, or is more carefully guardedthan the right of every individual to the possession and control of his own person, free from all restraint or interference from others Both Roe v. Wade, 410 U.S. 113 (1973) and Planned Parenthood v. Casey 506 U.S. 833 (1992), protected rights to privacy, autonomy, and personal choice. See also A.L.A. v. West Valley City, 26 F.3d 989, 990 (10th Cir.1994) (There is no dispute that confidential medical information is entitled to constitutional privacy protection.); According to A. Rahman Ford, JD, PhD, Undue infringement by the federal government upon so sacrosanct a right as the bodily integrity of private persons must be viewed as paternalistic, Victorian and an affront to the freedoms inherent in the Constitution itself.
Notwithstanding the aboveand again, in an abundance of cautionit is our sincerest interest to adhere to the FDAs interpretation of the laws and have several specific questions that we would like the FDA to kindly provide answers to:
Our clinic is simply providing medical treatments to consenting patients using cells from their own body during a medical procedure which does not invoke oversight by the federal government. We would like to specifically request a meeting with the FDA commissioner to better explain the procedures that have successfully helped thousands of people.
We look forward to your responses to our questions above. Feel free to contact me if additional information is required.
- Vertex invests in gene therapy manufacturing - BioPharma-Reporter.com - November 10th, 2019
- [Weekly Funding Roundup] Startups raised $53.3M, a drop of 75.8 pc from last week - YourStory - November 10th, 2019
- Pet Care Startup Wiggles Raises $1 Mn, Will Expand Its Footprint - Inc42 Media - November 10th, 2019
- Stem Cell Research and Hair Transplants How Far Have We Come? - Science Times - October 31st, 2019
- New NCCN Guidelines Debut to Manage Complications and Improve Readiness for Stem Cell Transplant Recipients - Yahoo Finance - October 31st, 2019
- Animal Stem Cell Therapy Market Sales Overview, Market Size, Opportunities, Demands, Market Share and Growth Analysis 2017 2025 - Health News Office - October 29th, 2019
- Acorn Biolabs partners with Executive Health Centre to become first clinic in North America to offer non-invasive stem cell collection - Canada... - October 24th, 2019
- Brooks Koepka slips on wet concrete, withdraws from CJ Cup - Golfweek - October 21st, 2019
- New research center to explore muscle health and disease - Newswise - October 18th, 2019
- Opinion: Neighborhood Health Clinic contributes to the overall wellbeing of Naples - Naples Daily News - October 18th, 2019
- Magenta Therapeutics Appoints Jan Pinkas as Senior Vice President, Head of Translational Sciences and Announces Transition of Chief Scientific Officer... - October 18th, 2019
- The global wound care market is growing at a CAGR of over 5% during the forecast period20182024 - Yahoo Finance - October 15th, 2019
- Saving rhinos with stem cells; $5.5 billion stem cell ballot measure readied - The San Diego Union-Tribune - October 12th, 2019
- BEYOND LOCAL: Expert recommends 'path of cautious optimism' about the future of stem cell treatment - ThoroldNews.com - October 12th, 2019
- Microbiome research needs a gut check - The Globe and Mail - October 12th, 2019
- BEYOND LOCAL: Expert recommends 'path of cautious optimism' about the future of stem cell treatment - GuelphToday - October 11th, 2019
- Biohack Your Way To Beauty And Health Using Your DNA And Stem Cells At These Wellness Retreats Around The World - Singapore Tatler - October 11th, 2019
- I donated my embryos years ago. Now I'm friends with the mom who received them - Yahoo Lifestyle - October 11th, 2019
- Man with at least 17 children sues fertility clinic for being 'incredibly irresponsible' with his sperm - Genetic Literacy Project - October 11th, 2019
- Senior, caregivers conference and expo coming Oct. 11 - The Daily Courier - October 9th, 2019
- Stem cell research is a good thing | Opinion - Chart - October 6th, 2019
- Regenerative medicine today: Are diabetes and vascular disease treatments ready for the clinic? - Science Magazine - October 5th, 2019
- Dr Naveen Pemmaraju Outlines the Symptoms of Myelofibrosis - AJMC.com Managed Markets Network - October 5th, 2019
- Businesses Sponsor Another Season Of Movies In The Park Square - Osprey Observer - October 5th, 2019
- Stem Cell Manufacturing | Research Report Overview By Top Key Players, Opportunities, Key Drivers, Application and Regional Outlook To 2027 -... - October 5th, 2019
- Sigilon Therapeutics approaches the clinic - Vantage - September 20th, 2019
- Research report explores the Animal Stem Cell Therapy Market - Zebvo - September 20th, 2019
- 'It feels amazing,' says Alabama man now first in the state to be free of sickle cell after gene therapy - Face2Face Africa - September 20th, 2019
- Michael Schumacher Is 'Conscious', Released From Paris Hospital After Experimental Treatment - International Business Times - September 20th, 2019
- Fighting for a cure: Tennis benefit to fund ALS research - Auburn Villager - September 20th, 2019
- Living With a Secondary Blood Cancer - Curetoday.com - September 20th, 2019
- Scientists Discover New Strategy That May Protect Against Hair-Loss During Cancer Treatments - Good News Network - September 20th, 2019
- Clinical trial of stem cell therapy for traumatic spinal ... - September 17th, 2019
- Autologous stem cell transplant - Type - Mayo Clinic - June 1st, 2019
- Stem cell therapy for hip | Mayo Clinic Connect - May 11th, 2019
- Next Generation Stem Cell - Professional medical clinic - April 7th, 2019
- N.Y. Attorney General Sues Manhattan Stem Cell Clinic ... - April 6th, 2019
- ThriveMD | Colorado's Experts in Stem Cells & Regenerative ... - March 29th, 2019
- Top Rated Stem Cell Therapy Clinic in Denver & Vail ... - March 16th, 2019
- South Florida Stem Cell Center | Regenerative Therapy Clinic - March 16th, 2019
- Mayo Clinic Q and A: Stem cell therapy for arthritis ... - March 7th, 2019
- COPD and stem cell treatment | Mayo Clinic Connect - March 7th, 2019
- GARM Stem Cell Clinic | Roatan - March 2nd, 2019
- Stem Cell Clinic Treatment Jupiter FL Alternative ... - March 1st, 2019
- Is This Stem-Cell Clinic Really Making Cancer Vaccines ... - February 12th, 2019
- Stem cells treatment clinic - Effective stem cell treatment - February 1st, 2019
- Vitality Healthcare - Home - January 28th, 2019
- About Us - U.S. Stem Cell Clinic - December 19th, 2018
- Brandon Stem Cell Clinic - December 19th, 2018
- Illinois Stem Cell Clinic - Illinois Stem Cell Clinic ... - October 5th, 2018
- Wisconsin Stem Cell Clinic - September 19th, 2018
- World Stem Cell Clinic - For a better quality of life | WSCC - June 18th, 2018
- Stem Cell Clinic Palmetto - Stem Cell Therapy Greenwood ... - June 18th, 2018
- Top Stem Cell Therapy Clinic in Vail & Denver, Colorado ... - September 20th, 2017
- Stem Cell Therapy - American Regenerative Clinic, Stem ... - September 19th, 2017
- Zika kills brain cancer cells, may find use as therapy - The San Diego Union-Tribune - September 5th, 2017
- FDA Reaffirms Its Commitment to the Approval of Stem Cell Therapies Amidst Enforcement Actions Against ... - Lexology (registration) - September 5th, 2017
- US FDA steps up enforcement against unscrupulous stem cell firms - BioPharma-Reporter.com - September 3rd, 2017
- FDA Reaffirms Its Commitment to the Approval of Stem Cell Therapies Amidst Enforcement Actions Against ... - JD Supra (press release) - September 3rd, 2017
- Around the world - Bend Bulletin - August 29th, 2017
- Daily on Healthcare: Lack of bare counties doesn't solve Obamacare's problems - Washington Examiner - August 29th, 2017
- How a UCSF study could change the lives of babies in the womb and maybe help California's stem cell program in ... - San Francisco Business Times - August 25th, 2017
- Stem Cell Study for Dogs - MyWabashValley - August 23rd, 2017
- Joint Preservation vs. Replacement: What's Your Best Option? - Health Essentials from Cleveland Clinic (blog) - August 23rd, 2017
- Bio-inspired Materials Give Boost to Regenerative Medicine - Bioscience Technology - August 22nd, 2017
- Fraud Alert! Unproven Stem Cell Use Prompts International Call to Action - American Council on Science and Health - August 20th, 2017
- Friends come together for benefit concert for Joni Eickhoff - Grand Island Independent - August 16th, 2017
- 'Unexpected fountain of youth' found in cardiac stem cells, researcher says - FOX31 Denver - August 16th, 2017
- New Mayo Clinic facility aims to increase lungs available for transplant - First Coast News - August 10th, 2017
- Surrey teen rallies stem cell donors to help with 'desperate' need for South Asians - Surrey Now-Leader - August 2nd, 2017
- Tampa Florida Stem Cell Clinic - Don't Operate - Regenerate - July 12th, 2017
- Dorothy Jean Kercheval Garrigan - The Messenger (subscription) - July 12th, 2017
- Private clinics are peddling untested stem cell treatments it's unethical and dangerous - Yahoo News UK - July 9th, 2017
- Private clinics' unproven stem cell treatment is unsafe and unethical ... - Business Standard - July 9th, 2017
- Stem Cells Play a Role in Acute Myeloid Leukemia Relapse - Technology Networks - June 30th, 2017
- NBA Star John Salley Partners with Stem Cell Centers of Excellence ... - Market Exclusive - June 30th, 2017
- Making Babies, No Sex Necessary - The Atlantic - June 28th, 2017
- Stem Cell Stem Cell Treatments by Clinic 42 - June 25th, 2017
- Powerful boost for bad skin days - Inquirer.net - June 22nd, 2017
- Here's Why US Stem Cell Inc (OTCMKTS:USRM) Shares Just ... - The Oracle Dispatch - June 21st, 2017